Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Krebs Biochemicals & Industries Ltd Stock Analysis

Small Cap
Evaluated by 191 users | BSE: 524518 | NSE: KREBSBIO |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Jun'13Sep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed -1.1%-9.82%-14.17%-4.33%-8.06%-27.51%-29.8%-32.07%-40.47%-61.45%-48.11%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 72.470.89.2001.33.533.847.833.453.737
Y-o-Y Gr. Rt.--2.3%-87.1%-100%NANA173.6%856.9%41.4%-30.1%60.7%-
Adjusted EPS (Rs.) -7.14-17.9-12.42-3.52-20.11-12.87-11.41-12.4-12.08-16.04-14.45-16.47
Y-o-Y Gr. Rt.-NANANANANANANANANANA-
Book Value per Share (Rs.) 41.9323.56.452.92-9.276.911.04-12.49-8.59-18.14-23.91-23.42
Adjusted Net Profit -6.7-17.6-12.2-3.5-19.8-17.4-16.2-17.6-20.1-28.9-28.4-36
Net Op. Cash Flow (Rs. Cr.) -4.67.3-1.239.4-90.5-15.3-11.2-6.23.9-35.5-14.6-
Debt to Cash Flow from Ops -18.6311.75-59.731.89-1.35-2-4.24-9.0813.7-1.87-6.94-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Krebs Biochemicals & Industries Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales -3%110.8%16.7%60.7%
Adjusted EPS NANANANA
Book Value per Share -200.2-228.200
Share Price 20.9% 15.4% 12.3% 80%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Jun'13Sep'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) -15.47-55.34-98.38-75.06-90.55-111.24-224.16216.43125.29147.0183.7469.6
Operating Profit Margin (%) 0.29-5.34-115.1100-961.72-226.62-22.2-20.44-55.53-32.73-66.95
Net Profit Margin (%) -9.24-24.93-133.6200-1349.51-460.05-52.23-42.06-86.43-52.81-97.07
Debt to Equity 2.193.7211.6525.86-13.343.2732.19-3.16-3.74-2.03-2.16-
Working Capital Days 3854012,408007,1061,488201158243179205
Cash Conversion Cycle 14987778001,149366-17-32-11-
Loading price chart...
Entity Percentage Holding
Promoters 72.74%
Institutions 0.01%
Non-Institutions 27.25%
Pledged *3.723.720.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

Krebs Biochemicals & Industries Ltd's earnings have grown by 0%, whereas share price has appreciated 15.4% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

Krebs Biochemicals & Industries Ltd share price has appreciated 20.9% annually (CAGR) over the past ten years.

Data is not available for this company.

Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade.

KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of

Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade.

KBIL went into public in the year March 1994 to part finance its fermentation technology project. KBIL has a strong shareholding community of over 10000 spread across all parts of the country.

KBIL’s manufacturing Unit-I is located at Regadichelika Village, Nellore Dist., Andhra Pradesh, India. Products manufactured from Unit I facility are Ephedrine, Pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, viz., cough, cold etc.

The facility at Unit II is being used to manufacture a basket of fermentation products viz., Lovastatin, Simvastatin, (all cholesterol reducing agents) and Vitamin C and its salts (neutraceuticals), which has wider applications in pharma, feeds, foods beverages etc. The company is focussing on the research and development of new bio molecules and genetically engineered products by synthetic and biological approaches. The manufacturing facility is developed in an area of 83.79 acres and comprises of Administration Block, Fermentation Block, Extraction Column, Hydrogenation & Synthetic Blocks, Quality Control Department, Quality Assurance Block, Ware House, Pseudoephedrine Block, Solvent Yard and Canteen etc.

KBIL has received ISO 9002 certification for its Unit-I situated at Nellore from Yarsley International Certifications Services accredited by United Kingdom Accreditation Services (U.K.A.S.) in the year 2001. Unit I is also accredited with European Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM).

Product range of the company includes:

Bulk activities

Synthetic

  • Lavastatin
  • Simvastatin
  • I -Ephedrochiloride
  • l - Ephedrine Sulphate
  • l - Ephedrine Base (Liquid)
  • d - Pseudoephedrine Hydrochloride
  • d - Pseudoephedrine Sulphate
  • d - Pseudoephedrine Base
  • dl - Ephedrine Base
  • n - Methyl Ephedrine
  • d - Ephedrine Bitartarate
  • Vitamin C
  • Vitamin C (Coated)

Herbal

  • Calcium Sennosides - 20% & 60%
  • Garcinia Combogia Powdered Extract
  • Capsaicin - 50/100

Intermediates

  • Crude Lovastatin
  • Simvastatin Ammonium Salt

Products in pipeline

  • Pravastatin Sodium

Achievements/ recognition:

  • ISO 9002 in November 2001 
  • EDQM July 2003 
  • USFDA in November 2003 
  • ISO 9001 – 2000 in March 2004 
  • WHO GMP certification in November 2002 and renewed in March 2005
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback